Miral Patel
YOU?
Author Swipe
View article: Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition
Retrospective review of metastatic hormone receptor-positive inflammatory breast cancer patients reveals poor responses to cyclin dependent kinase 4/6 inhibition Open
Background Patients with inflammatory breast cancer (IBC) have aggressive biology and relatively inferior responses to standard-of-care (SOC) therapies. Understanding the efficacy of SOC therapies in IBC is critical to optimize outcomes. O…
View article: Use of natural language processing to identify patients with inflammatory breast cancer across a health-care system
Use of natural language processing to identify patients with inflammatory breast cancer across a health-care system Open
Early identification and referral of inflammatory breast cancer remains challenging within large health-care systems, limiting access to specialized care. We developed and evaluated an artificial intelligence–driven platform integrating na…
View article: Supplementary Figure SF1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Supplementary Figure SF1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Somatic mutations identified by whole exome sequencing. Oncoplot representing the most common somatic mutations assessed by whole exome sequencing (WES) in tumors obtained from patients (n = 23) at the time of diagnosis. Genes with mutatio…
View article: Supplementary Figure SF3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Supplementary Figure SF3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
SUPPLEMENTARY FIGURE SF3. Box plots showing relationship between tumor mutational burden and pathological response.
View article: SUPPLEMENTARY TABLE ST2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
SUPPLEMENTARY TABLE ST2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Type of Surgery and Adjuvant Therapy Received.
View article: SUPPLEMENTARY TABLE ST3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
SUPPLEMENTARY TABLE ST3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Representativeness of Study Participants.
View article: Supplementary Figure SF2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Supplementary Figure SF2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
SUPPLEMENTARY FIGURE SF2. Somatic mutations in genes commonly altered in TNBC. Oncoplot showing somatic mutations reported as commonly prevalent in other TNBC cohorts.
View article: SUPPLEMENTARY TABLE ST1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
SUPPLEMENTARY TABLE ST1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Molecular Subtypes and Pathological Response.
View article: Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer
Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Open
Purpose: To develop deep learning models for predicting the pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST) in patients with triple-negative breast cancer (TNBC) based on pretreatment multiparametric breast MRI an…
View article: Supplementary Figure SF3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Supplementary Figure SF3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
SUPPLEMENTARY FIGURE SF3. Box plots showing relationship between tumor mutational burden and pathological response.
View article: Figure 3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Figure 3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Survival outcomes. A, Kaplan–Meier plot of EFS for all patients. B, Kaplan–Meier plot of EFS separated by pathological response. C, Kaplan–Meier plot of MFS for all patients. D, Kaplan–Meier plot of MFS separate…
View article: Figure 2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Figure 2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Genomic alterations and pathological response to therapy. Oncoplot showing somatic mutations in the EGFR pathway assessed by WES for each patient sample obtained at the time of diagnosis (n = 23). TMB was defined as the number of so…
View article: Table 1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Table 1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Baseline clinicopathologic characteristics and associations with pathologic response
View article: SUPPLEMENTARY TABLE ST2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
SUPPLEMENTARY TABLE ST2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Type of Surgery and Adjuvant Therapy Received.
View article: Supplementary Figure SF2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Supplementary Figure SF2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
SUPPLEMENTARY FIGURE SF2. Somatic mutations in genes commonly altered in TNBC. Oncoplot showing somatic mutations reported as commonly prevalent in other TNBC cohorts.
View article: SUPPLEMENTARY TABLE ST1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
SUPPLEMENTARY TABLE ST1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Molecular Subtypes and Pathological Response.
View article: Table 3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Table 3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Exposure to panitumumab
View article: Data from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Data from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Purpose:Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the hi…
View article: Figure 1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Figure 1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Response to AC. Waterfall plot showing percent sonographic volumetric change to initial AC chemotherapy received prior to enrollment in study. One of the 43 patients enrolled in this study is not represented on this plot as an ultrasound w…
View article: Supplementary Figure SF1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Supplementary Figure SF1 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Somatic mutations identified by whole exome sequencing. Oncoplot representing the most common somatic mutations assessed by whole exome sequencing (WES) in tumors obtained from patients (n = 23) at the time of diagnosis. Genes with mutatio…
View article: SUPPLEMENTARY TABLE ST3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
SUPPLEMENTARY TABLE ST3 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Representativeness of Study Participants.
View article: Table 2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Table 2 from Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
TRAEs
View article: Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study Open
Purpose: Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the h…
View article: Multiparametric MRI–based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer
Multiparametric MRI–based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer Open
Triple-negative breast cancer (TNBC) is often treated with neoadjuvant systemic therapy (NAST). We investigated if radiomic models based on multiparametric Magnetic Resonance Imaging (MRI) obtained early during NAST predict pathologic comp…
View article: Deep Learning based Semantic Segmentation for Buildings Detection from Remote Sensing Images
Deep Learning based Semantic Segmentation for Buildings Detection from Remote Sensing Images Open
Building extraction from remote sensing images is the process of automatically identifying and extracting the boundaries of buildings from high-resolution aerial or satellite images. The extracted building footprints can be used for a vari…
View article: Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment
Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment Open
Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive group of tumors that are defined by the absence of estrogen and progesterone receptors and lack of ERBB2 (formerly HER2 or HER2/neu) overexpression…
View article: Deep Learning Architecture U-Net Based Road Network Detection from Remote Sensing Images
Deep Learning Architecture U-Net Based Road Network Detection from Remote Sensing Images Open
Roads are the foundation of human civilisation and one of the most important routes of transportation. For the city planning, vehicle traffic control, road network monitoring, map updating and GPS navigation, the study of road extraction i…
View article: Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs
Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs Open
We trained and validated a deep learning model that can predict the treatment response to neoadjuvant systemic therapy (NAST) for patients with triple negative breast cancer (TNBC). Dynamic contrast enhanced (DCE) MRI and diffusion-weighte…
View article: Imaging Features Following Breast Explant Surgery: A Pictorial Essay
Imaging Features Following Breast Explant Surgery: A Pictorial Essay Open
Breast implants can be removed with breast explantation surgery (BES) for various reasons, including patient dissatisfaction, capsular contracture, implant infection or rupture, breast implant-associated anaplastic large cell lymphoma, and…
View article: Breast Angiosarcoma: Imaging Features With Histopathologic Correlation
Breast Angiosarcoma: Imaging Features With Histopathologic Correlation Open
Breast angiosarcoma is a rare malignancy of endothelial origin that can be categorized as primary angiosarcoma (PAS) or secondary angiosarcoma (SAS) based on etiology. Primary angiosarcoma typically affects younger women with no known risk…